| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0029-7844(99)00359-2 |
| P698 | PubMed publication ID | 10511348 |
| P2093 | author name string | Archer DF | |
| Dain MP | |||
| Furst K | |||
| Tipping D | |||
| Vandepol C | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 498-503 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Obstetrics and Gynecology | Q7075543 |
| P1476 | title | A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group | |
| P478 | volume | 94 |
| Q44636672 | Comparative bioequivalence studies with Estradot® and Menorest® transdermal systems |
| Q43028516 | DHEA, important source of sex steroids in men and even more in women |
| Q36533630 | Dehydroepiandrosterone, androgens and the mammary gland |
| Q44240051 | Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches |
| Q38935535 | Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator |
| Q35928422 | GPR30 is necessary for estradiol-induced desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the rat hypothalamus. |
| Q36892918 | HT update: spotlight on estradiol/norethindrone acetate combination therapy |
| Q47385631 | Hispanic women's experience with "el cambio de vida". |
| Q46141973 | Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction |
| Q40953559 | Intravaginal DHEA, by a strictly local action, exerts beneficial effects on both vaginal atrophy symptoms and sexual dysfunction |
| Q37016116 | Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen |
| Q35948695 | Neoplasia of the female reproductive tract: effects of hormone therapy |
| Q35009434 | Optimisation of treatment by applying programmable rate-controlled drug delivery technology |
| Q24246213 | Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes |
| Q28268346 | Pharmacology of estrogens and progestogens: influence of different routes of administration |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
Search more.